These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 24548143)

  • 1. Intravenous application of allogenic peripheral blood-derived mesenchymal stem cells: a safety assessment in 291 equine recipients.
    Broeckx S; Borena BM; Zimmerman M; Mariën T; Seys B; Suls M; Duchateau L; Spaas JH
    Curr Stem Cell Res Ther; 2014; 9(6):452-7. PubMed ID: 24548143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retrospective analysis of local injection site adverse reactions associated with 230 allogenic administrations of bone marrow-derived mesenchymal stem cells in 164 horses.
    Ursini TL; Amelse LL; Elkhenany HA; Odoi A; Carter-Arnold JL; Adair HS; Dhar MS
    Equine Vet J; 2019 Mar; 51(2):198-205. PubMed ID: 29992618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allogenic mesenchymal stem cells as a treatment for equine degenerative joint disease: a pilot study.
    Broeckx S; Suls M; Beerts C; Vandenberghe A; Seys B; Wuertz-Kozak K; Duchateau L; Spaas JH
    Curr Stem Cell Res Ther; 2014; 9(6):497-503. PubMed ID: 25175766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Equine allogeneic bone marrow-derived mesenchymal stromal cells elicit antibody responses in vivo.
    Pezzanite LM; Fortier LA; Antczak DF; Cassano JM; Brosnahan MM; Miller D; Schnabel LV
    Stem Cell Res Ther; 2015 Apr; 6(1):54. PubMed ID: 25889095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allo-antibody production after intraarticular administration of mesenchymal stem cells (MSCs) in an equine osteoarthritis model: effect of repeated administration, MSC inflammatory stimulation, and equine leukocyte antigen (ELA) compatibility.
    Barrachina L; Cequier A; Romero A; Vitoria A; Zaragoza P; Vázquez FJ; Rodellar C
    Stem Cell Res Ther; 2020 Feb; 11(1):52. PubMed ID: 32028995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and tracking of intrathecal allogeneic mesenchymal stem cell transplantation in healthy and diseased horses.
    Barberini DJ; Aleman M; Aristizabal F; Spriet M; Clark KC; Walker NJ; Galuppo LD; Amorim RM; Woolard KD; Borjesson DL
    Stem Cell Res Ther; 2018 Apr; 9(1):96. PubMed ID: 29631634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The regenerative medicine laboratory: facilitating stem cell therapy for equine disease.
    Borjesson DL; Peroni JF
    Clin Lab Med; 2011 Mar; 31(1):109-23. PubMed ID: 21295725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Practical considerations for clinical use of mesenchymal stem cells: From the laboratory to the horse.
    Barrachina L; Romero A; Zaragoza P; Rodellar C; Vázquez FJ
    Vet J; 2018 Aug; 238():49-57. PubMed ID: 30103915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tracking of autologous adipose tissue-derived mesenchymal stromal cells with in vivo magnetic resonance imaging and histology after intralesional treatment of artificial equine tendon lesions--a pilot study.
    Geburek F; Mundle K; Conrad S; Hellige M; Walliser U; van Schie HT; van Weeren R; Skutella T; Stadler PM
    Stem Cell Res Ther; 2016 Feb; 7():21. PubMed ID: 26830812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple intravenous injections of allogeneic equine mesenchymal stem cells do not induce a systemic inflammatory response but do alter lymphocyte subsets in healthy horses.
    Kol A; Wood JA; Carrade Holt DD; Gillette JA; Bohannon-Worsley LK; Puchalski SM; Walker NJ; Clark KC; Watson JL; Borjesson DL
    Stem Cell Res Ther; 2015 Apr; 6(1):73. PubMed ID: 25888916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concepts and challenges in the use of mesenchymal stem cells as a treatment for cartilage damage in the horse.
    Zayed M; Adair S; Ursini T; Schumacher J; Misk N; Dhar M
    Res Vet Sci; 2018 Jun; 118():317-323. PubMed ID: 29601969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Contribution of Adipose Tissue-Derived Mesenchymal Stem Cells and Platelet-Rich Plasma to the Treatment of Chronic Equine Laminitis: A Proof of Concept.
    Angelone M; Conti V; Biacca C; Battaglia B; Pecorari L; Piana F; Gnudi G; Leonardi F; Ramoni R; Basini G; Dotti S; Renzi S; Ferrari M; Grolli S
    Int J Mol Sci; 2017 Oct; 18(10):. PubMed ID: 29019941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persistence of fluorescent nanoparticle-labelled bone marrow mesenchymal stem cells in vitro and after intra-articular injection.
    Grady ST; Britton L; Hinrichs K; Nixon AJ; Watts AE
    J Tissue Eng Regen Med; 2019 Feb; 13(2):191-202. PubMed ID: 30536848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allogeneic major histocompatibility complex-mismatched equine bone marrow-derived mesenchymal stem cells are targeted for death by cytotoxic anti-major histocompatibility complex antibodies.
    Berglund AK; Schnabel LV
    Equine Vet J; 2017 Jul; 49(4):539-544. PubMed ID: 27862236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Equine allogeneic umbilical cord blood derived mesenchymal stromal cells reduce synovial fluid nucleated cell count and induce mild self-limiting inflammation when evaluated in an lipopolysaccharide induced synovitis model.
    Williams LB; Koenig JB; Black B; Gibson TW; Sharif S; Koch TG
    Equine Vet J; 2016 Sep; 48(5):619-25. PubMed ID: 26114736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of single intralesional treatment of surgically induced equine superficial digital flexor tendon core lesions with adipose-derived mesenchymal stromal cells: a controlled experimental trial.
    Geburek F; Roggel F; van Schie HTM; Beineke A; Estrada R; Weber K; Hellige M; Rohn K; Jagodzinski M; Welke B; Hurschler C; Conrad S; Skutella T; van de Lest C; van Weeren R; Stadler PM
    Stem Cell Res Ther; 2017 Jun; 8(1):129. PubMed ID: 28583184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mesenchymal stem cells for treatment of musculoskeletal disease in horses: Relative merits of allogeneic versus autologous stem cells.
    Colbath AC; Dow SW; McIlwraith CW; Goodrich LR
    Equine Vet J; 2020 Sep; 52(5):654-663. PubMed ID: 31971273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of efficacy and safety of single versus repeated intra-articular injection of allogeneic neonatal mesenchymal stem cells for treatment of osteoarthritis of the metacarpophalangeal/metatarsophalangeal joint in horses: A clinical pilot study.
    Magri C; Schramme M; Febre M; Cauvin E; Labadie F; Saulnier N; François I; Lechartier A; Aebischer D; Moncelet AS; Maddens S
    PLoS One; 2019; 14(8):e0221317. PubMed ID: 31465445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distribution and persistence of technetium-99 hexamethyl propylene amine oxime-labelled bone marrow-derived mesenchymal stem cells in experimentally induced tendon lesions after intratendinous injection and regional perfusion of the equine distal limb.
    Sole A; Spriet M; Padgett KA; Vaughan B; Galuppo LD; Borjesson DL; Wisner ER; Vidal MA
    Equine Vet J; 2013 Nov; 45(6):726-31. PubMed ID: 23574488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isolation of mesenchymal stem cells from equine umbilical cord blood.
    Koch TG; Heerkens T; Thomsen PD; Betts DH
    BMC Biotechnol; 2007 May; 7():26. PubMed ID: 17537254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.